An EMA committee has recommended approval of Alvotech’s AVT06, a biosimilar to Bayer’s blockbuster ophthalmology drug Eylea.

Harbour BioMed has entered a strategic partnership with Otsuka focusing on the development of HBM7020 for treating autoimmune ...

Dedicated datasets highlight how social determinants of health can be used to improve overall standards of care.

The EC has approved argenx’s Vyvgart (efgartigimod alfa) 1000mg as a single agent for subcutaneous injection to treat CIDP.

David W Miller, CEO of Genesis Research Group, discusses how pharma's decade-long development approach is no longer fit for ...